The subject of the invention is the use of Simalikalactone E (SkE) as an anticancer agent, more particularly for preventing and/or treating epithelial and hematological cancers.
Simalikalactone E is a quassinoid isolated from an Amazonian plant of the family Simaroubaceae, i.e. the Quassia amara